Novabay Pharmaceuticals, Inc. (NBY) SEC Filing 8-K Material Event for the period ending Monday, July 1, 2019

SEC Filings

Novabay Pharmaceuticals, Inc.

CIK: 1568540 Ticker: NBY

View differences made from one to another to evaluate Novabay Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Novabay Pharmaceuticals, Inc..


Assess how Novabay Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Novabay Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Novabay Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: NBY
CIK: 1389545
Form Type: 8-K Corporate News
Accession Number: 0001437749-19-013120
Submitted to the SEC: Mon Jul 01 2019 8:32:05 AM EST
Accepted by the SEC: Mon Jul 01 2019
Period: Monday, July 1, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: